Merck & Co., Inc. $MRK Stock Holdings Cut by Independence Bank of Kentucky

Independence Bank of Kentucky lessened its position in Merck & Co., Inc. (NYSE:MRK) by 10.5% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 34,770 shares of the company’s stock after selling 4,076 shares during the period. Independence Bank of Kentucky’s holdings in Merck & Co., Inc. were worth $4,182,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Kingdom Financial Group LLC. bought a new position in shares of Merck & Co., Inc. during the 4th quarter valued at about $25,000. Abound Financial LLC acquired a new stake in Merck & Co., Inc. during the fourth quarter valued at approximately $26,000. Prosperity Bancshares Inc acquired a new stake in Merck & Co., Inc. during the fourth quarter valued at approximately $26,000. United Financial Planning Group LLC bought a new stake in Merck & Co., Inc. during the third quarter worth approximately $31,000. Finally, High Note Wealth LLC grew its position in Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after buying an additional 109 shares during the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Down 1.1%

NYSE:MRK traded down $1.35 during trading hours on Friday, hitting $123.72. 8,388,403 shares of the company’s stock traded hands, compared to its average volume of 10,797,806. The stock’s fifty day moving average price is $118.83 and its two-hundred day moving average price is $116.28. The firm has a market cap of $305.56 billion, a P/E ratio of 34.85, a P/E/G ratio of 2.68 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. Merck & Co., Inc. has a twelve month low of $76.66 and a twelve month high of $130.29.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm had revenue of $16.29 billion during the quarter, compared to analyst estimates of $15.85 billion. During the same period last year, the company posted $2.22 EPS. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, research analysts expect that Merck & Co., Inc. will post 5.17 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, July 8th. Investors of record on Monday, June 15th were given a dividend of $0.85 per share. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.7%. Merck & Co., Inc.’s payout ratio is presently 95.77%.

Analyst Upgrades and Downgrades

Several research firms have issued reports on MRK. Bank of America upped their price target on Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Wells Fargo & Company lifted their target price on Merck & Co., Inc. from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday. Wall Street Zen lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Weiss Ratings downgraded Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday, May 15th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $142.00 price target on shares of Merck & Co., Inc. in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $132.72.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA approved KEYTRUDA and KEYTRUDA QLEX, each combined with Padcev, for use before and after surgery in adults with muscle-invasive bladder cancer. This expands Merck’s flagship oncology franchise and could add to future revenue. Article Title
• Positive Sentiment: Analyst sentiment remains constructive, with Morgan Stanley slightly raising its price target and RBC Capital reiterating a Buy rating. That suggests Wall Street still sees upside despite the stock’s recent run. Article Title
• Positive Sentiment: Merck continues to attract investor attention thanks to strong year-to-date performance, a solid dividend yield, and a long record of dividend growth, which may support demand for the shares. Article Title
• Neutral Sentiment: Recent coverage also notes Merck is one of the more widely watched healthcare names on Zacks, but these mentions do not appear to add any new fundamental catalyst on their own. Article Title
• Negative Sentiment: Despite the upbeat news flow, the shares also face ongoing valuation and post-KEYTRUDA exclusivity concerns, which may limit upside if investors focus on Merck’s long-term patent risk. Article Title

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.